Mepolizumab Shows Real-World Gains in Severe Nasal Polyps

A real-world Italian study found that mepolizumab significantly reduced nasal polyp scores and improved quality of life in adults with severe chronic rhinosinusitis with nasal polyps. At 12 months, 42% achieved disease control and 20% were on track for remission. Researchers suggest benefits may continue beyond the study period.